５ October 2022
EFPIA Japan

Takaufumi Horii appointed new Vice Chair of EFPIA JapanTOKYO – 5 October 2022 – European Federation of Pharmaceutical Industries and Associations
Japan (EFPIA Japan) announced today that Takafumi Horii (President and RepresentativeDirector, AstraZeneca) has been appointed the new Vice Chair of EFPIA Japan effective 30
September, with terms until March 2023. This appointment is associated with the resignation ofYoshiaki Aono.
In addition, Shashank Deshpande (Representative Director, Chairman and President, Nippon
Boehringer Ingelheim Co., Ltd.), Kasper Bødker Mejlvang (President and Representative Director,Novo Nordisk Pharma Ltd.) and Takafumi Horii have also been appointed new Board of Directors
in the extraordinal general assembly meeting held on 15 September.
Together with Leo Lee (Novartis Pharma K.K.) who continues to serve in his position of ViceChair, Takafumi Horii will support Takahiko Iwaya (Sanofi K.K.), the Chair of EFPIA Japan.
“The unsettling world situation underscores the need to build a more efficient, flexible andsustainable healthcare system that can adapt to a volatile and uncertain future as well as thespeed of innovation. EFPIA Japan remains committed to contributing its expertise and knowledge
to debates with stakeholders for finding solutions”, says Takafumi Horii upon the appointment.
EFPIA Japan Board Members as of 30 September 2022
Chair

Takahiko Iwaya(Sanofi K.K.)

Vice Chairs

Leo Lee(Novartis Pharma K.K.)

Takafumi Horii(AstraZeneca K.K.)

Board ofPaul Lirette(GlaxoSmithKline K.K.)

Directors

Julio Triana(Bayer Yakuhin, Ltd.)

Shuhei Sekiguchi(Janssen Pharmaceutical K.K.)

Kanako Kikuchi(UCB Japan Co., Ltd.)Shashank Deshpande(Nippon Boehringer Ingelheim Co., Ltd.)New

Kasper Bødker Mejlvang(Novo Nordisk Pharma Ltd.)

NewAlexandre De Muralt(Merck Biopharma Co., Ltd.)

Director General

Takeo Morooka

EFPIA JapanTokyo Opera City Tower, 3-20-2, Nishi Shinjuku, Shinjuku-ku, Tokyo, JapanNew

About EFPIA Japan (http://efpia.jp/)
Established in April 2002, EFPIA Japan represents 23 R&D-based European pharmaceuticalcompanies operating in Japan. In 2021, combined sales from the member companies accounted
for roughly 26% of the pharmaceutical market in Japan. The mission of EFPIA Japan is to“Contribute to healthcare and patients in Japan through the early introduction of innovative
medicines and vaccines”. EFPIA Japan aims to strengthen dialogue with decision-makers in orderto improve Japanese healthcare for all.

About EFPIA (European Federation of Pharmaceutical Industries and Associations)(https://www.efpia.eu/)
The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents thebiopharmaceutical industry operating in Europe. Through its direct membership of 37 nationalassociations, 38 leading pharmaceutical companies and a growing number of small and mediumsized enterprises (SMEs), EFPIA’s mission is to create a collaborative environment that enables
our members to innovate, discover, develop and deliver new therapies and vaccine s for people
across Europe, as well as contribute to the European economy.

Contact:Yuko Kidoguchi
EFPIA Japan Communications Committee
1-6-5 Marunouchi Chiyoda-ku, Tokyo 100-8268
Bayer Holding Ltd.
Tel: 03-6266-7757
Email: yuko.kidoguchi@bayer.com

EFPIA JapanTokyo Opera City Tower, 3-20-2, Nishi Shinjuku, Shinjuku-ku, Tokyo, Japan

President & Representative Director
AstraZeneca K.K.

Takafumi Horii (Taka) is President & Representative Director of AstraZenecaK.K. and leads the business in Japan with 3,400 employees acrossCommercial, R&D and Operations.
EXPERIENCE
Prior to his role at AstraZeneca K.K., Taka served as Senior Vice President, Head of Japan Oncology
Business Unit and a member of the Global Oncology Leadership Team, as well as being part of theJapan Country Committee at Takeda Pharmaceutical Company.
Previously, Taka held various leadership roles at Takeda across the world, including VP & Area Headof the Near-east, Middle-east and Africa covering 21 countries in the region, President & General
Manager in Taiwan, VP & Head of Strategy of Emerging Market, and Head of Strategy for China.
Externally, Taka served as an executive committee member at the PhRMA in the Middle East andAfrica when based in Dubai, as a standing board member and chairperson of the market accesscommittee at the IRPMA (International Research-Based Pharmaceutical Manufacturers) and a vicechairperson of the Pharmaceutical & Medical Committee at the JCCI (The Japan Chamber ofCommerce and industry), demonstrating leadership in the industry to improve healthcare systems
across countries, as well as improving access to medicine for patients.
Taka started his career at the global HQ, Canon Inc. After that, he joined a US-based IT start-up
company to launch their business in Japan where he led a consulting delivery team, providing
consulting services to major Japanese and multinational clients in pharma and non-pharma industries.
Throughout his career, Taka has consistently taken on bigger responsibilities, as well as expanding hisleadership experience through his international assignments in Dubai, Taiwan, Shanghai andSingapore.
AWARDS“Top Employer in Middle East as a Regional Award” as a recognition of a holistic HR framework toempower Country Managers and HR Business partners.
“Top 100 Healthcare Leader Award” by IFAH as a recognition of contribution in emerging markets
including improving access to medicine for patients.
EDUCATION
MBA, Darden Graduate School of Business, University of Virginia, the USA.

1